Lipoprotein Lipase Activity Is Associated With Severity of Angina Pectoris

BackgroundRaised triglyceride-rich lipoproteins significantly increase the risk for cardiovascular disease. Variation in the activity of the enzyme lipoprotein lipase (LPL), which is crucial in the removal of these lipoproteins, may therefore modulate this risk. Methods and ResultsPostheparin levels of LPL activity and mass were measured in a large cohort of male coronary artery disease patients participating in the Regression Growth Evaluation Statin Study (REGRESS), a lipid-lowering regression trial. In addition, the relationships between LPL activity and mass and severity of angina pectoris according to the NYHA classification and silent ischemia on 24-hour ambulatory ECG monitoring were assessed. Patients in different LPL activity quartiles and mass had different severities of angina; a total of 47% of patients in the lowest LPL quartile reported class III or IV angina. In contrast, only 29% in the highest activity quartile (P =0.002) had severe angina. These parameters were supported by ambulatory ECG results, for which the total ischemic burden in the lowest LPL activity quartile was 36.5±104.1 mm×min compared with 14.8±38.8 mm×min in the highest quartile of LPL activity (P =0.001). LPL activity levels were strongly correlated with LPL mass (r =0.70, P <0.0001). A significant association between the LPL protein mass and NYHA class (P =0.012) was also demonstrated. ConclusionsWe have demonstrated a significant relationship between LPL mass and activity and severity of ischemia as defined by angina class and ambulatory ECG. These results suggest that LPL influences risk for coronary artery disease by both catalytic and noncatalytic mechanisms.

[1]  J. Kobayashi,et al.  Effect of troglitazone on plasma lipid metabolism and lipoprotein lipase. , 2000, British journal of clinical pharmacology.

[2]  P. Wilson,et al.  A common truncation variant of lipoprotein lipase (Ser447X) confers protection against coronary heart disease: the Framingham Offspring Study , 1999, Clinical genetics.

[3]  C. Barton,et al.  Effect of increased afterload on cardiac lipoprotein lipase and VLDL receptor expression. , 1999, Biochimica et biophysica acta.

[4]  W. Mack,et al.  Triglyceride-rich lipoproteins and progression of atherosclerosis. , 1998, European heart journal.

[5]  M. Omata,et al.  Altered myocardial vasodilatation in patients with hypertriglyceridemia in anatomically normal coronary arteries. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[6]  J. Wilhjelm,et al.  Echo-lucency of computerized ultrasound images of carotid atherosclerotic plaques are associated with increased levels of triglyceride-rich lipoproteins as well as increased plaque lipid content. , 1998, Circulation.

[7]  E. Boerwinkle,et al.  The Asn9 variant of lipoprotein lipase is associated with the — 93G promoter mutation and an increased risk of coronary artery disease , 1998, Clinical genetics.

[8]  E. Boerwinkle,et al.  The Asn9 variant of lipoprotein lipase is associated with the -93G promoter mutation and an increased risk of coronary artery disease. The Regress Study Group. , 1998 .

[9]  T. Rabelink,et al.  NO activity in familial combined hyperlipidemia: potential role of cholesterol remnants. , 1997, Cardiovascular research.

[10]  K. Schenck-Gustafsson,et al.  Transient triglyceridemia decreases vascular reactivity in young, healthy men without risk factors for coronary heart disease. , 1997, Circulation.

[11]  A. Baron,et al.  Endothelial dysfunction is associated with cholesterol levels in the high normal range in humans. , 1997, Circulation.

[12]  R. Gibbons,et al.  Coronary endothelial dysfunction in humans is associated with myocardial perfusion defects. , 1997, Circulation.

[13]  S. Miura,et al.  Antiatherogenic effects of a novel lipoprotein lipase-enhancing agent in cholesterol-fed New Zealand white rabbits. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[14]  D. Harrison,et al.  Expression of multiple isoforms of nitric oxide synthase in normal and atherosclerotic vessels. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[15]  J. Buring,et al.  Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. , 1997, Circulation.

[16]  L. Krogh,et al.  1.P.46 Detecting mutations in the lipoprotein lipase gene. Establishment and testing of a screening method , 1997 .

[17]  H. Zouali,et al.  1.P.26 Prevalence of common lipoprotein lipase (LPL) gene mutation Ser447Stop is increased while prevalence of Asn291Ser mutation is decreased in centenarians , 1997 .

[18]  E. Boerwinkle,et al.  Genetic Variant Showing a Positive Interaction With β-Blocking Agents With a Beneficial Influence on Lipoprotein Lipase Activity, HDL Cholesterol, and Triglyceride Levels in Coronary Artery Disease Patients: The Ser447-Stop Substitution in the Lipoprotein Lipase Gene , 1997 .

[19]  G. Plotnick,et al.  Effect of a single high-fat meal on endothelial function in healthy subjects. , 1997, The American journal of cardiology.

[20]  M J Davies,et al.  Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995. , 1996, Circulation.

[21]  A. Zwinderman,et al.  The Asp9 Asn mutation in the lipoprotein lipase gene is associated with increased progression of coronary atherosclerosis. REGRESS Study Group, Interuniversity Cardiology Institute, Utrecht, The Netherlands. Regression Growth Evaluation Statin Study. , 1996, Circulation.

[22]  H. Crijns,et al.  Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris. REGRESS Study Group. , 1996, Circulation.

[23]  M. Hayden,et al.  Premature atherosclerosis in patients with familial chylomicronemia caused by mutations in the lipoprotein lipase gene. , 1996, The New England journal of medicine.

[24]  M. Hayden,et al.  A frequently occurring mutation in the lipoprotein lipase gene (Asn291Ser) results in altered postprandial chylomicron triglyceride and retinyl palmitate response in normolipidemic carriers. , 1996, Journal of lipid research.

[25]  J. Hokanson,et al.  Plasma Triglyceride Level is a Risk Factor for Cardiovascular Disease Independent of High-Density Lipoprotein Cholesterol Level: A Metaanalysis of Population-Based Prospective Studies , 1996, Journal of cardiovascular risk.

[26]  W. Mack,et al.  Triglyceride-rich lipoproteins and the progression of coronary artery disease. , 1995, Current opinion in lipidology.

[27]  G J Boerma,et al.  Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). , 1995, Circulation.

[28]  A. Quyyumi,et al.  Nitric oxide activity in the human coronary circulation. Impact of risk factors for coronary atherosclerosis. , 1995, The Journal of clinical investigation.

[29]  G. Renier,et al.  Lipoprotein lipase synergizes with interferon gamma to induce macrophage nitric oxide synthetase mRNA expression and nitric oxide production. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[30]  M. Hayden,et al.  A lipoprotein lipase mutation (Asn291Ser) is associated with reduced HDL cholesterol levels in premature atherosclerosis , 1995, Nature Genetics.

[31]  K. Iwasaki,et al.  The novel compound NO-1886 increases lipoprotein lipase activity with resulting elevation of high density lipoprotein cholesterol, and long-term administration inhibits atherogenesis in the coronary arteries of rats with experimental atherosclerosis. , 1993, The Journal of clinical investigation.

[32]  T. Noakes,et al.  Postprandial lipemia and chylomicron clearance in athletes and in sedentary men. , 1989, The American journal of clinical nutrition.

[33]  J. Brunzell.  Familial lipoprotein lipase deficiency and other causes of the chylomicronemia syndrome , 1989 .

[34]  M. Nagano,et al.  Lipoprotein lipase activity in ischaemic and anoxic myocardium. , 1987, Basic research in cardiology.

[35]  P. Nilsson-ehle,et al.  A stable, radioactive substrate emulsion for assay of lipoprotein lipase. , 1976, Journal of lipid research.